Get in touch
Please contact us to discuss how working with Myriad can maximise and secure R&D funding opportunities for your business.
Contact usThe Enhanced R&D Intensive Support (ERIS) scheme pays loss-making SMEs up to 26.97% of qualifying R&D spend. See who qualifies, how it works and how to claim.
The Enhanced R&D Intensive Support (ERIS) scheme is the R&D tax relief for loss-making SMEs that spend a large share of their budget on R&D. For accounting periods beginning on or after 1 April 2024, it is worth up to 26.97p for every £1 of qualifying spend.
Most companies now claim under the Merged Scheme, so ERIS is the exception for companies that meet specific conditions.
ERIS applies to accounting periods beginning on or after 1 April 2024 and sits alongside the Merged Scheme. The rules on what counts as qualifying R&D expenditure are the same under both; what differs is how your credit is calculated.
The Merged Scheme gives a taxable expenditure credit of 20%. ERIS works more like the old SME scheme: you claim an additional deduction, then surrender the resulting loss in exchange for a cash credit.
You must meet all three of the following:
The loss condition is strict. Without a trading loss before the additional deduction, you get neither the deduction nor the payable credit.
The intensity condition generally applies to the period you're claiming. There’s also a one year grace period; you can also meet it if you met it in your previous 12-month accounting period and made a valid SME or ERIS claim on expenditure incurred on or after 1 April 2023.
To qualify as an R&D-intensive SME, your relevant R&D expenditure must be at least 30% of your total relevant expenditure.
Relevant R&D expenditure is the cost eligible for R&D relief in the period, whether or not you claim it. It also includes any relevant R&D expenditure of any connected companies.
Total relevant expenditure is broader: specifically, it includes trading expenditure per your P&L, qualifying pre-trading expenditure and any amounts deducted in your tax computation. It excludes any related amortisation added back in your tax computation minus any payments to connected companies. You should include connected companies’ relevant expenditure in your total.
Where your accounting period doesn't line up with a connected company's, or a connected company is overseas, you'll need to allocate costs using a reasonable method. A day-based split can work, or you can attribute costs by when they were incurred if spending is uneven. Use the same basis consistently and be ready to explain it to HMRC.
There is a one-year grace period if you miss the R&D intensity threshold; if you miss it two years in a row, you’ll have to claim through the Merged Scheme.
ERIS works in two steps:
The surrenderable loss is the lower of:
The unrelieved amount excludes any amounts that receive or could have received sideways relief setting current year trading losses against total profits. It also excludes any amount that received any other relief or any group relief.
In real terms, that works out at 26.97p for every £1 of qualifying spend (186% x 14.5%). Under the Merged Scheme, the same spend is worth around 15p at the 25% main rate of corporation tax.
Here is what that looks like in practice:
Company A is a loss-making SME with total relevant expenditure of £500,000, of which £250,000 is qualifying R&D. Its R&D intensity is 50%, well above the 30% threshold.
It claims an additional deduction of £215,000 (86% of £250,000), taking its total deduction to £465,000 (the usual 100% deduction of £500,000 in expenditure and an extra 86% of the R&D expenditure). If its loss is large enough to surrender the full £465,000, it receives a payable credit of £67,425 (14.5%).
Under the Merged Scheme, the same spend would be worth around £37,500.
That's £29,925 more cash from the same R&D spend.
Yes. Your credit for an accounting period can't exceed the PAYE and NIC cap, unless you're exempt. The cap is £20,000 plus 300% of your company's relevant PAYE and NIC liabilities for the period. In practice, most companies doing genuine UK-based R&D are comfortably within it.
Under ERIS, any excess above the cap isn't carried forward, whereas under the Merged Scheme it is. For the full calculation, see our guide: The PAYE/NIC Cap for R&D Tax Credits
Yes. You can choose the Merged Scheme even if you qualify for ERIS, but you can't claim both for the same expenditure. Profit-making SMEs and SMEs that don't meet the intensity condition will need to claim under the Merged Scheme. If some of your expenditure can't be claimed under ERIS (for example, because of sector de minimis limits, as for Northern Irish companies), it may still be claimable under the Merged Scheme.
For most loss-making, R&D-intensive SMEs, ERIS pays more. The exception is where the PAYE and NIC cap is likely to apply, because the Merged Scheme carries the excess forward and ERIS doesn't, so model both before you file. For a side-by-side comparison, see our guide: Merged vs ERIS: Which R&D Tax Scheme Should I Use?
Northern Ireland has its own treatment. SMEs registered in Northern Ireland claiming ERIS aren't subject to the restrictions on payments to overseas contractors or externally provided workers.
Instead, any ERIS claimed is considered de minimis state aid and is subject to a cap of €300,000. This cap applies to the total additional relief received through ERIS (compared to if you had claimed with the Merged Scheme) in the three years before the date the claim was made.
Companies with a registered office in Northern Ireland with a trade in goods, or a trade which involves the relevant activities in relation to the electricity market must follow the NI ERIS provisions unless they opt out.
You can only opt out if your business does not meet the trade requirements, and you do it by completing the online Additional Information Form when you make your claim.
If you think your company could qualify for ERIS, or you're not sure how connected companies affect your intensity calculation, don't leave it to chance. Contact Myriad to discuss your situation.
The Enhanced R&D Intensive Support (ERIS) scheme pays loss-making SMEs up to 26.97% of qualifying R&D spend. See who qualifies, how it works and how to claim.
HMRC plans to exclude AVEC and VGEC from tax-EBITDA in the Corporate Interest Restriction from 1 January 2027. See who's affected and what to check.
AVEC replaces the old film and TV tax reliefs on 1 April 2027. See how the move works, what happens if you don't opt in, and what to check now.
Please contact us to discuss how working with Myriad can maximise and secure R&D funding opportunities for your business.
Contact us